Angiopoietin-like protein 2 and angiopoietin-like protein 6 levels in patients with nonalcoholic fatty liver disease

Erkan, Gülbanu; Muratoglu, Suzan; Erçin, Uğur; Bi̇lgi̇han, Ayşe

doi:10.5114/aoms.2016.61811

Cited by 2 publications

(2 citation statements)

References 21 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NAFLD is becoming one of the most common liver diseases worldwide, whose complex pathogenesis is closely associated with metabolic disorders such as obesity [3,37,38]. To understand the specific mechanisms involved in this process is an urgent necessity [39].…”

Section: Discussionmentioning

confidence: 99%

FGF-21 Levels and Liver Inflammatory Biomarkers in Obese Subjects After Weight Loss.

et al. 2021

View full text Add to dashboard Cite

IntroductionPrevious studies have hypothesized Fibroblast growth factor 21 (FGF-21) as a potential biomarker of the inflammation associated to liver diseases, which is also receiving high attention for its potential application concerning the management of obesity and co-morbidities. This study aimed to analyze the response of FGF-21 after a weight loss intervention and the relationships with other putative inflammatory liver biomarkers.Material and methodsSixty-six obese participants from the RESMENA study were evaluated at baseline and after following a 6-months energy restriction treatment. Anthropometrical, body composition by DXA, routine laboratory measurements, which included transaminases and gamma-glutamyl transferase (GGT) were analyzed by standardized methods. Moreover, FGF-21, M30-fragment (M30) and plasminogen activator inhibitor-1 (PAI-I) were analyzed as recognized liver inflammatory related biomarkers with specific ELISA Kits.ResultsMost measurements related with hepatic damage, inflammation and adiposity status improved at the end of the 6-months nutritional intervention. In addition, ΔFGF-21 shifts evidenced statistical relationships with changes in ΔM30, ΔGGT and ΔPAI. The reduction of M30 showed significant associations with changes in transaminases. Furthermore, PAI-I changes were related with ΔM30 and ΔGGT regardless of weight loss. A linear regression model was set up to assess the influence of ΔPAI-I and ΔM30 on the variability of ΔFGF-21 (23.8%) adjusted by weight loss.ConclusionsThese results evidenced interactions of some liver inflammatory mediators, specifically M30 and PAI-I with FGF-21. Thus, more investigation about FGF-21 is required given that this protein could be a biomarker of the obesity-inflammation-liver process.

show abstract

Section: Discussionmentioning

confidence: 99%

FGF-21 Levels and Liver Inflammatory Biomarkers in Obese Subjects After Weight Loss.

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The role of AGF in the development of NAFLD has not been investigated, but elevated serum AGF level, similar to FGF21, could indicate mitochondrial stress and reflect the progression of NAFLD. 140…”

mentioning

confidence: 99%

Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease

Chang

Kong

et al. 2022

Gut and Liver

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is accompanied by a complex and multifactorial pathogenesis with sequential progressions from inflammation to fibrosis and then to cancer. This heterogeneity interferes with the development of precise diagnostic and prognostic strategies for NAFLD. The current approach for the diagnosis of simple steatosis, steatohepatitis, and cirrhosis mainly consists of ultrasonography, magnetic resonance imaging, elastography, and various serological analyses. However, individual dry and wet biomarkers have limitations demanding an integrative approach for the assessment of disease progression. Here, we review diagnostic strategies for simple steatosis, steatohepatitis and hepatic fibrosis, followed by potential biomarkers associated with fat accumulation and mitochondrial stress. For mitochondrial stress indicators, we focused on fibroblast growth factor 21 (FGF21), growth differentiation factor 15 (GDF15), angiopoietin-related growth factor and mitochondrial-derived peptides. Each biomarker may not strongly indicate the severity of steatosis or steatohepatitis. Instead, multidimensional analysis of different groups of biomarkers based on pathogenic mechanisms may provide decisive diagnostic/prognostic information to develop a therapeutic plan for patients with NAFLD. For this purpose, mitochondrial stress indicators, such as FGF21 or GDF15, could be an important component in the multiplexed and contextual interpretation of NAFLD. Further validation of the integrative evaluation of mitochondrial stress indicators combined with other biomarkers is needed in the diagnosis/prognosis of NAFLD.

show abstract

Angiopoietin-like protein 2 and angiopoietin-like protein 6 levels in patients with nonalcoholic fatty liver disease

Cited by 2 publications

References 21 publications

FGF-21 Levels and Liver Inflammatory Biomarkers in Obese Subjects After Weight Loss.

FGF-21 Levels and Liver Inflammatory Biomarkers in Obese Subjects After Weight Loss.

Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease

Contact Info

Product

Resources

About